BeyondSpring (NASDAQ:BYSI) Trading Down 0.6% - Should You Sell?

Key Points

• Analyst sentiment: BeyondSpring has a consensus "Sell" rating, with Weiss Ratings reiterating a sell (d+) recommendation.
• Price/market data: Shares were down 0.6% to $1.60 (intraday low $1.545) on light volume, implying a market cap of about $65.8M and trading below its 200‑day moving average of $1.74.
• Fundamentals and ownership: The company reported an EPS of ($0.05), beating estimates of ($0.54), while institutional investors own ~40.3% of the stock and Geode Capital increased its stake by 16.9% to 368,682 shares.

Shares of BeyondSpring Inc. (NASDAQ:BYSI - Get Free Report) were down 0.6% during trading on Friday . The stock traded as low as $1.5450 and last traded at $1.60. Approximately 22,271 shares changed hands during trading, a decline of 15% from the average daily volume of 26,164 shares. The stock had previously closed at $1.61.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a "sell (d+)" rating on shares of BeyondSpring in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, BeyondSpring has a consensus rating of "Sell".

BeyondSpring Stock Performance

The company has a market capitalization of $65.79 million, a PE ratio of -10.67 and a beta of 0.56. The business has a fifty day moving average price of $1.52 and a 200 day moving average price of $1.74.

BeyondSpring (NASDAQ:BYSI - Get Free Report) last issued its earnings results on Wednesday, March 25th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.49.

Institutional Investors Weigh In On BeyondSpring

An institutional investor recently raised its position in BeyondSpring stock. Geode Capital Management LLC lifted its holdings in shares of BeyondSpring Inc. (NASDAQ:BYSI - Free Report) by 16.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 368,682 shares of the company's stock after acquiring an additional 53,198 shares during the quarter. Geode Capital Management LLC owned about 0.91% of BeyondSpring worth $601,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 40.29% of the company's stock.

About BeyondSpring

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring's pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company's lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.